MicroRNA-182-5p Promotes Cell Invasion and Proliferation by Down Regulating FOXF2, RECK and MTSS1 Genes in Human Prostate Cancer

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Feb 6

PMID 23383207

Citations 86

Authors

Hiroshi Hirata

Koji Ueno

Varahram Shahryari

Guoren Deng

Yuichiro Tanaka

Z Laura Tabatabai

Yuji Hinoda

Rajvir Dahiya

Affiliations

Soon will be listed here.

Abstract

Recently miR-182 has been reported to be over-expressed in prostate cancer (PC) tissues, however detailed functional analysis of miR-182-5p has not been carried out. The purpose of this study was to: 1. analyze the function of miR-182-5p in prostate cancer, 2. assess its usefulness as a tumor marker, 3. identify miR-182-5p target genes in PC, 4. investigate the potential for miR-182-5p inhibitor to be used in PC treatment. Initially we found that miR-182-5p expression was significantly higher in prostate cancer tissues and cell lines compared to normal prostate tissues and cells. Moreover high miR-182-5p expression was associated with shorter overall survival in PC patients. To study the functional significance of miR-182-5p, we knocked down miR-182-5p with miR-182-5p inhibitor. After miR-182-5p knock-down, prostate cancer cell proliferation, migration and invasion were decreased. We identified FOXF2, RECK and MTSS1 as potential target genes of miR-182-5p using several algorithms which was confirmed by 3'UTR luciferase assay and Western analysis. Knock-down of miR-182-5p also significantly decreased in vivo prostate tumor growth. In conclusion this is the first report documenting that over-expression of miR-182-5p is associated with prostate cancer progression and potentially useful as a prognostic biomarker. Also knock down of miR-182-5p in order to increase expression of tumor suppressor genes FOXF2, RECK and MTSS1 may be of therapeutic benefit in prostate cancer treatment.

Citing Articles

Role of the Forkhead box family protein FOXF2 in the progression of solid tumor: systematic review.

Zheng Y, Wu L, Hu Z, Liao H, Li X J Cancer Res Clin Oncol. 2024; 151(1):14.

PMID: 39724282 PMC: 11671575. DOI: 10.1007/s00432-024-06047-z.

Diagnostic Value and Molecular Function of MicroRNAs in Endometrial Diseases: A Systematic Review.

Kluz N, Kowalczyk E, Wasilewska M, Gil-Kulik P Cancers (Basel). 2024; 16(13).

PMID: 39001478 PMC: 11240806. DOI: 10.3390/cancers16132416.

MiR-21 Regulates Growth and Migration of Cervical Cancer Cells by RECK Signaling Pathway.

Aguilar-Martinez S, Campos-Viguri G, Medina-Garcia S, Garcia-Flores R, Deas J, Gomez-Ceron C Int J Mol Sci. 2024; 25(7).

PMID: 38612895 PMC: 11012906. DOI: 10.3390/ijms25074086.

Eslami M, Khazeni S, Mohammadi Khanaghah X, Asadi M, Ansari M, Garjan J Cancer Cell Int. 2023; 23(1):182.

PMID: 37635248 PMC: 10463971. DOI: 10.1186/s12935-023-03022-5.

Pediatric T-cell acute lymphoblastic leukemia blast signature and MRD associated immune environment changes defined by single cell transcriptomics analysis.

Bhasin S, Thomas B, Summers R, Sarkar D, Mumme H, Pilcher W Sci Rep. 2023; 13(1):12556.

PMID: 37532715 PMC: 10397284. DOI: 10.1038/s41598-023-39152-z.

References

Clark J, Thomas D, Choong P, Dass C . RECK--a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer. Cancer Metastasis Rev. 2007; 26(3-4):675-83. DOI: 10.1007/s10555-007-9093-8. View

Oue N, Sato A, Hasegawa Y, Yamamoto H, Matsubara A, Yasui W . Wnt5a signaling is involved in the aggressiveness of prostate cancer and expression of metalloproteinase. Oncogene. 2010; 29(14):2036-46. DOI: 10.1038/onc.2009.496. View

Ribas J, Ni X, Haffner M, Wentzel E, Salmasi A, Chowdhury W . miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res. 2009; 69(18):7165-9. PMC: 2861586. DOI: 10.1158/0008-5472.CAN-09-1448. View

Cheng L, Zincke H, Blute M, Bergstralh E, Scherer B, Bostwick D . Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer. 2001; 91(1):66-73. DOI: 10.1002/1097-0142(20010101)91:1<66::aid-cncr9>3.0.co;2-p. View

Segura M, Hanniford D, Menendez S, Reavie L, Zou X, Alvarez-Diaz S . Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci U S A. 2009; 106(6):1814-9. PMC: 2634798. DOI: 10.1073/pnas.0808263106. View

Inui M, Martello G, Piccolo S . MicroRNA control of signal transduction. Nat Rev Mol Cell Biol. 2010; 11(4):252-63. DOI: 10.1038/nrm2868. View

Roemeling S, Roobol M, de Vries S, Gosselaar C, van der Kwast T, Schroder F . Prevalence, treatment modalities and prognosis of familial prostate cancer in a screened population. J Urol. 2006; 175(4):1332-6. DOI: 10.1016/S0022-5347(05)00698-1. View

Jiang L, Mao P, Song L, Wu J, Huang J, Lin C . miR-182 as a prognostic marker for glioma progression and patient survival. Am J Pathol. 2010; 177(1):29-38. PMC: 2893648. DOI: 10.2353/ajpath.2010.090812. View

Reis S, Pontes-Junior J, Antunes A, DallOglio M, Dip N, Passerotti C . miR-21 may acts as an oncomir by targeting RECK, a matrix metalloproteinase regulator, in prostate cancer. BMC Urol. 2012; 12:14. PMC: 3431982. DOI: 10.1186/1471-2490-12-14. View

10.

Liu Z, Liu J, Segura M, Shao C, Lee P, Gong Y . MiR-182 overexpression in tumourigenesis of high-grade serous ovarian carcinoma. J Pathol. 2012; 228(2):204-15. DOI: 10.1002/path.4000. View

11.

Fabbri M, Croce C, Calin G . MicroRNAs. Cancer J. 2008; 14(1):1-6. DOI: 10.1097/PPO.0b013e318164145e. View

12.

Yoshida Y, Ninomiya K, Hamada H, Noda M . Involvement of the SKP2-p27(KIP1) pathway in suppression of cancer cell proliferation by RECK. Oncogene. 2011; 31(37):4128-38. DOI: 10.1038/onc.2011.570. View

13.

Rabien A, Ergun B, Erbersdobler A, Jung K, Stephan C . RECK overexpression decreases invasive potential in prostate cancer cells. Prostate. 2011; 72(9):948-54. DOI: 10.1002/pros.21498. View

14.

Ormestad M, Astorga J, Landgren H, Wang T, Johansson B, Miura N . Foxf1 and Foxf2 control murine gut development by limiting mesenchymal Wnt signaling and promoting extracellular matrix production. Development. 2006; 133(5):833-43. DOI: 10.1242/dev.02252. View

15.

Zhang L, Liu T, Huang Y, Liu J . microRNA-182 inhibits the proliferation and invasion of human lung adenocarcinoma cells through its effect on human cortical actin-associated protein. Int J Mol Med. 2011; 28(3):381-8. DOI: 10.3892/ijmm.2011.679. View

16.

Chan J, Holick C, Leitzmann M, Rimm E, Willett W, Stampfer M . Diet after diagnosis and the risk of prostate cancer progression, recurrence, and death (United States). Cancer Causes Control. 2006; 17(2):199-208. DOI: 10.1007/s10552-005-0413-4. View

17.

Schaefer A, Jung M, Mollenkopf H, Wagner I, Stephan C, Jentzmik F . Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer. 2009; 126(5):1166-76. DOI: 10.1002/ijc.24827. View

18.

Zhang B, Pan X, Cobb G, Anderson T . microRNAs as oncogenes and tumor suppressors. Dev Biol. 2006; 302(1):1-12. DOI: 10.1016/j.ydbio.2006.08.028. View

19.

Guttilla I, White B . Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J Biol Chem. 2009; 284(35):23204-16. PMC: 2749094. DOI: 10.1074/jbc.M109.031427. View

20.

Pang Y, Young C, Yuan H . MicroRNAs and prostate cancer. Acta Biochim Biophys Sin (Shanghai). 2010; 42(6):363-9. DOI: 10.1093/abbs/gmq038. View